Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rotavirus vaccine, live, oral, pentavalent + diphtheria-tetanus-pertussis (whole cell)-hepatitis B vaccine
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Oral, Intramuscular
01
Overview
RotaTeq + Tritanrix HepB refers to the co-administration of two distinct pediatric vaccines. RotaTeq, developed by Merck, is a pentavalent live oral vaccine containing five human-bovine reassortant rotaviruses (G1, G2, G3, G4, and P1[8]) indicated for the prevention of rotavirus gastroenteritis. Tritanrix HepB, developed by GSK, is a combination vaccine containing diphtheria and tetanus toxoids, inactivated whole-cell Bordetella pertussis, and recombinant hepatitis B surface antigen (HBsAg). This combination is typically administered during routine infant immunization schedules (e.g., at 2, 4, and 6 months of age) to provide broad protection against multiple infectious diseases while minimizing the number of healthcare visits. Clinical trials have demonstrated that the co-administration of these vaccines is generally well-tolerated and does not significantly interfere with the immune response to the individual components.
- Other names
- DTPw-HBDTP-HepBPentavalent rotavirus vaccineDiphtheria-tetanus-whole cell pertussis-hepatitis B vaccine
02
Targets
VP7 (Rotavirus VP7)HBsAg (Hepatitis B surface antigen)TT (Tetanus toxoid)VP4 (Rotavirus VP4)
Beyond the preview
Go deeper on rotavirus vaccine, live, oral, pentavalent + diphtheria-tetanus-pertussis (whole cell)-hepatitis B vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rotavirus vaccine, live, oral, pentavalent + diphtheria-tetanus-pertussis (whole cell)-hepatitis B vaccine.